NAV

Carmoterol

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Carmoterol is a long acting beta-2 agonist indicated in the treatment of COPD, asthma, and chronic bronchitis.

Generic Name
Carmoterol
DrugBank Accession Number
DB15784
Background

Not Available

Type
Small Molecule
Groups
Experimental
Structure
3D
Similar Structures
Weight
Average: 368.433
Monoisotopic: 368.173607261
Chemical Formula
C21H24N2O4
Synonyms
  • Carmoterol
  • Quinoterol
External IDs
  • CHF 4226
  • CHF-4226
  • TA-2005
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Used in combination to manageAsthmaCombination Product in combination with: Mometasone furoate (DB14512)•••••••••••••••••
Used in combination for symptomatic treatment ofAsthmaCombination Product in combination with: Budesonide (DB01222)•••••••••••••••••••• ••••••
Adjunct therapy in management ofAsthma••••••••••••••••••••••••• ••••••
Used in combination to manageBronchoconstrictionCombination Product in combination with: Tiotropium (DB01409)•••••••••••••••••• •••••••••••••
Used in combination to manageChronic bronchitisCombination Product in combination with: Tiotropium (DB01409)•••••••••••••••••• •••••••••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
LUXNID 2/200 MCG INHALASYON IÇIN TOZ IÇEREN BLISTER,60 DOZCarmoterol (2 mcg) + Ciclesonide (200 mcg)PowderRespiratory (inhalation)NEUTEC İNHALER İLAÇ SAN. VE TİC. A.Ş.2014-02-052022-11-19Turkey flag
LUXNID 2/200 MCG INHALASYON IÇIN TOZ IÇEREN KAPSÜL,120 KAPSÜLCarmoterol (2 mcg) + Ciclesonide (200 mcg)PowderRespiratory (inhalation)NEUTEC İNHALER İLAÇ SAN. VE TİC. A.Ş.2014-02-082022-11-19Turkey flag
LUXNID 2/200 MCG INHALASYON IÇIN TOZ IÇIEREN KAPSÜL,60 KAPSÜLCarmoterol (2 mcg) + Ciclesonide (200 mcg)PowderRespiratory (inhalation)NEUTEC İNHALER İLAÇ SAN. VE TİC. A.Ş.2014-02-082022-11-19Turkey flag
LUXNID 2/400 MCG INHALASYON IÇIN TOZ IÇEREN BLISTER ,60 DOZCarmoterol (2 mcg) + Ciclesonide (400 mcg)PowderRespiratory (inhalation)NEUTEC İNHALER İLAÇ SAN. VE TİC. A.Ş.2014-02-052022-11-19Turkey flag
LUXNID 2/400 MCG INHALASYON IÇIN TOZ IÇEREN KAPSÜL,120 KAPSÜLCarmoterol (2 mcg) + Ciclesonide (400 mcg)PowderRespiratory (inhalation)NEUTEC İNHALER İLAÇ SAN. VE TİC. A.Ş.2014-02-082022-11-19Turkey flag

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
9810NUL4D1
CAS number
147568-66-9
InChI Key
IHOXNOQMRZISPV-YJYMSZOUSA-N
InChI
InChI=1S/C21H24N2O4/c1-13(11-14-3-5-15(27-2)6-4-14)22-12-19(25)16-7-9-18(24)21-17(16)8-10-20(26)23-21/h3-10,13,19,22,24-25H,11-12H2,1-2H3,(H,23,26)/t13-,19+/m1/s1
IUPAC Name
8-hydroxy-5-[(1R)-1-hydroxy-2-{[(2R)-1-(4-methoxyphenyl)propan-2-yl]amino}ethyl]-1,2-dihydroquinolin-2-one
SMILES
COC1=CC=C(C[C@@H](C)NC[C@H](O)C2=CC=C(O)C3=C2C=CC(=O)N3)C=C1

References

General References
  1. TITCK Product Information: Luxnid (carmoterol hydrochloride/ciclesonide) powder for inhalation [Link]
  2. TITCK Product Information: ROPITAL (carmoterol and tiotropium) powder for inhalation [Link]
ChemSpider
57545
ChEMBL
CHEMBL1094785
ZINC
ZINC000034853956
PDBe Ligand
WHJ
Wikipedia
Carmoterol
PDB Entries
2y02

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
PhaseStatusPurposeConditionsCount
2CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)3
1CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
PowderRespiratory (inhalation)1 mcg
PowderRespiratory (inhalation)2 mcg
PowderRespiratory (inhalation)4 mcg
PowderRespiratory (inhalation)
Capsule; powderRespiratory (inhalation)
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0188 mg/mLALOGPS
logP1.95ALOGPS
logP1.49Chemaxon
logS-4.3ALOGPS
pKa (Strongest Acidic)8.52Chemaxon
pKa (Strongest Basic)9.76Chemaxon
Physiological Charge1Chemaxon
Hydrogen Acceptor Count5Chemaxon
Hydrogen Donor Count4Chemaxon
Polar Surface Area90.82 Å2Chemaxon
Rotatable Bond Count7Chemaxon
Refractivity106.72 m3·mol-1Chemaxon
Polarizability39.77 Å3Chemaxon
Number of Rings3Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleYesChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-014i-0629000000-f0cd211092217acb1714
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-00lj-0917000000-042f317e81e0a61f974f
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-01t9-2593000000-8966834811d5816d3521
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-01b9-0954000000-373298dbe2b6b7d3978d
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0l0w-4926000000-9155cecf0b12bab70e1c
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-01s9-0913000000-aa6eb8e08bbd5d59fe9e
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-186.18327
predicted
DeepCCS 1.0 (2019)
[M+H]+188.57884
predicted
DeepCCS 1.0 (2019)
[M+Na]+194.49138
predicted
DeepCCS 1.0 (2019)

Drug created at August 24, 2020 13:53 / Updated at May 14, 2021 01:08